Pricing Log in Create free account

Avenue Therapeutics, Inc. (ATXI) vs Valion Bio, Inc. (VBIO)

Avenue Therapeutics, Inc. and Valion Bio, Inc. are both Biotechnology companies. Valion Bio, Inc. is the larger, with a market value of $1.1M against $680.0K — 1.6× the size. Across the 10 metrics below, Avenue Therapeutics, Inc. leads on 8 and Valion Bio, Inc. on 2.

Valuation

Metric ATXI VBIO Biotechnology median
P/E n/m n/m 10.60
P/S n/m 0.14 9.40
P/B 2.49 0.02 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.05 n/m 0.66
EV/Sales n/m 11.09 9.02
Earnings yield (197.67%) (40,026.00%) (32.88%)
Free cash flow yield (97.68%) (22,510.36%) (23.13%)

Profitability

Metric ATXI VBIO Biotechnology median
Gross margin — (58.09%) 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (163.30%) (489.30%) (51.96%)
Return on assets (90.50%) (104.96%) (46.06%)
Return on invested capital 0.00% (61.01%) 0.00%

Growth

Metric ATXI VBIO Biotechnology median
Revenue growth (TTM) — (49.63%) 6.76%
EPS growth (last fiscal year) 94.11% 60.16% 29.88%
Revenue growth, 5-year CAGR — 13.18% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ATXI VBIO Biotechnology median
Debt to equity 0.00 0.62 0.00
Current ratio 1.40 1.11 4.97
Net debt to EBITDA 0.93 0.79 1.01

Dividend

Metric ATXI VBIO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ATXI VBIO Biotechnology median
Market cap 680.00k 1.08m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack